10-Q: Catheter Precision Reports Q1 2026 Results, Acquires FLYTE

Catheter Precision, Inc. reported its Q1 2026 financial results, highlighting increased revenues from its cardiac electrophysiology and private aviation segments following the acquisition of FLYTE.

Summary

• Catheter Precision, Inc. reported its Q1 2026 results, showing total revenues of $432,000, a significant increase from $143,000 in the prior year period, driven by growth in both its cardiac electrophysiology and private aviation segments.
• The company incurred a net loss of $1,690,000 for the quarter, compared to a net loss of $4,045,000 in Q1 2025.
• Selling, general, and administrative expenses decreased by $926,000 due to reduced headcount and restructuring of sales compensation.
• Research and development expenses increased by $46,000, primarily due to consulting fees for VIVO software upgrades.
• The company completed the acquisition of FLYTE, a private aviation company, in February and March 2026, which contributed $184,000 in service revenue during the period.
• Catheter Precision has substantial doubt about its ability to continue as a going concern, with $0.4 million in cash and cash equivalents as of March 31, 2026, and plans to raise additional capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the substantial doubt about the company's ability to continue as a going concern, despite revenue growth and cost reductions.

Positives

• Total revenues increased by 202% to $432,000 in Q1 2026 from $143,000 in Q1 2025.
• Product revenue from the cardiac electrophysiology segment increased by $105,000, driven by higher sales of LockeT and VIVO System.
• Selling, general, and administrative expenses decreased by $926,000, indicating improved cost management.
• The acquisition of FLYTE diversified the company's revenue streams into the private aviation sector.

Negatives

• The company has substantial doubt about its ability to continue as a going concern, with only $0.4 million in cash and cash equivalents as of March 31, 2026.
• Net loss for the quarter was $1,690,000, although this is an improvement from the prior year's loss of $4,045,000.
• The company has an accumulated deficit of $311.2 million.
• The company expects operating losses and negative cash flows to continue in the foreseeable future.
• The company's common stock equity is near the minimum level required for NYSE American listing.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The private aviation market is competitive and sensitive to economic conditions.
• FLYTE's reliance on third-party aircraft operators and potential disruptions in their services pose a risk.
• The company faces risks related to pilot availability and increasing labor costs in the aviation sector.
• Potential for significant dilution to existing common stockholders due to the conversion of outstanding convertible preferred stock.
• The company has identified material weaknesses in internal control over financial reporting in the past.

Future Outlook

Management expects operating losses and negative cash flows to continue for the foreseeable future. The company plans to raise additional capital through public or private equity or debt financing to fulfill its operating and capital requirements for at least the next 12 months. However, there is no guarantee that such financing will be secured on favorable terms, or at all.

Management Comments

• Management's strategy is to become a leading medical device company in the field of cardiac electrophysiology.
• The company aims to establish VIVO as an integral tool used by cardiac electrophysiologists.
• FLYTE is positioned to compete in the developing urban air mobility (UAM), regional air mobility (RAM) and advanced air mobility (AAM) markets.

Industry Context

StockSavvy.ai notes that Catheter Precision's diversification into the private aviation sector through the FLYTE acquisition reflects a broader trend of companies seeking complementary revenue streams. However, the company's continued net losses and going concern doubts highlight the significant financial challenges in both the medical device and aviation industries.

Legal Proceedings

• An employment dispute with a former FLYTE employee alleging wrongful termination is proceeding through arbitration.

Related Party Transactions

• Notes payable to related parties, including David Jenkins, FatBoy Capital, L.P., and Jenkins Family Charitable Institute, totaling $1.8 million as of March 31, 2026.
• Lease agreements for aircraft with SEG Jets LLC, a related party.
• Royalty agreements with related parties for LockeT sales.
• Issuance of Series J Convertible Preferred Stock to David A. Jenkins and FatBoy Capital, L.P. in exchange for royalty rights.

Stakeholder Impact

• Existing common stockholders face significant dilution risk from the conversion of convertible preferred stock.
• The company's going concern status may impact investor confidence and the value of common stock.
• Employees may be affected by restructuring and potential operational changes due to liquidity challenges.

Next Steps

• Secure additional capital to fund operations and meet debt obligations.
• Continue to develop and commercialize VIVO and LockeT products.
• Integrate FLYTE's operations and realize anticipated strategic benefits.
• Address potential delisting from the NYSE American if minimum listing requirements are not maintained.

Key Dates

Recommendation

The company's severe liquidity constraints and substantial doubt about its ability to continue as a going concern, coupled with significant dilution risks from convertible securities, outweigh the reported revenue growth and cost control measures. The high probability of further capital raises on unfavorable terms or potential operational distress makes the stock a sell.

Keywords

Catheter Precision, Form 10-Q, Quarterly Report, Cardiac Electrophysiology, Private Aviation, FLYTE Acquisition, VIVO System, LockeT, Financial Results, Going Concern